MAPT and Alzheimer disease: Targeting the phosphorylation of tau protein is a potential treatment approach for AD, and while many drugs have been tested in preclinical studies, few have entered clinical trials; these include lithium salts, tideglusib, saracatinib, nilotinib, and others.